Skip to content

Clinical trials

Phase 2 Melanoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Melanoma Phase: Phase 2 Clear all

878 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200011
200115
200214
200323
200434
200540
200634
200733
200834
200928
201034
201136
201230
201338
201439
201535
201630
201729
201830
201936
202034
202144
202236
202328
202420
202526
202628

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed432
Terminated167
Unknown status77
Active, not recruiting70
Recruiting70
Withdrawn34
Not yet recruiting22
Suspended5
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)106
M.D. Anderson Cancer Center32
Bristol-Myers Squibb23
Memorial Sloan Kettering Cancer Center23
Hoffmann-La Roche12
Peking University Cancer Hospital & Institute12
GlaxoSmithKline11
H. Lee Moffitt Cancer Center and Research Institute10
Novartis Pharmaceuticals10
Melanoma Institute Australia9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Melanoma878
Neoplasm Metastasis60
Carcinoma, Renal Cell52
Carcinoma, Non-Small-Cell Lung51
Skin Neoplasms47
Brain Neoplasms46
Neoplasms45
Uveal Melanoma45
Breast Neoplasms32
Lung Neoplasms25

Trials

Showing 76 to 100 of 878. Each trial links to its page on Pharma Observatory.

778 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.